Heterogeneous copper concentrations in cancerous human prostate tissues

Prostate

Volumn 75, Issue 14, 2015, Pages 1510-1517

  Denoyer, Delphine ^a   Clatworthy, Sharnel A S ^a   Masaldan, Shashank ^a   Meggyesy, Peter M ^a   Cater, Michael A ^a,b  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

benign prostatic hyperplasia; copper; ionophore; prostate cancer; treatment

Indexed keywords

COPPER ION; COPPER; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; COPPER TISSUE LEVEL; DISEASE SEVERITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TISSUE LEVEL; VERY ELDERLY; BLOOD; METABOLISM; PROSTATIC NEOPLASMS; VICTORIA;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COPPER; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; VICTORIA;

EID: 84939254674     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23022     Document Type: Article

References (21)

1. Peng F, Lu X, Janisse J, Muzik O, Shields AF,. PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2. J Nucl Med 2006; 47: 1649-1652.
2. Cai H, Wu JS, Muzik O, Hsieh JT, Lee RJ, Peng F,. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. J Nucl Med 2014; 55: 622-628.
3. Cater MA, Haupt Y,. Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): Therapeutic indication for prostate cancer. Biochem J 2011; 436: 481-491.
4. Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S, Yan B, Reddy GP, Dou QP,. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 2007; 67: 1636-1644.
5. Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, McDonnell DP,. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res 2014; 74: 5819-5831.
6. Santini C, Pellei M, Gandin V, Porchia M, Tisato F, Marzano C,. Advances in copper complexes as anticancer agents. Chem Rev 2014; 114: 815-862.
7. Cater MA, Pearson HB, Wolyniec K, Klaver P, Bilandzic M, Paterson BM, Bush AI, Humbert PO, La Fontaine S, Donnelly PS, Haupt Y,. Increasing intracellular bioavailable copper selectively targets prostate cancer cells. ACS Chem Biol 2013; 8: 1621-1631.
8. Thoma C, Prostate cancer: Copper unlocks therapeutic potential of disulfiram. Nat Rev Urol 2014; 11: 664.
9. Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA,. Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis 2013; 16: 357-361.
10. Zaichick V, Nosenko S, Moskvina I,. The effect of age on 12 chemical element contents in the intact prostate of adult men investigated by inductively coupled plasma atomic emission spectrometry. Biol Trace Elem Res 2012; 147: 49-58.
11. Guess HA, Arrighi HM, Metter EJ, Fozard JL,. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990; 17: 241-246.
12. Malavolta M, Piacenza F, Basso A, Giacconi R, Costarelli L, Mocchegiani E,. Serum copper to zinc ratio: Relationship with aging and health status. Mech Ageing Dev 2015.
13. Golabek T, Darewicz B, Borawska M, Socha K, Markiewicz R, Kudelski J,. Copper, zinc, and Cu/Zn ratio in transitional cell carcinoma of the bladder. Urol Int 2012; 89: 342-347.
14. Cunzhi H, Jiexian J, Xianwen Z, Jingang G, Shumin Z, Lili D,. Serum and tissue levels of six trace elements and copper/zinc ratio in patients with cervical cancer and uterine myoma. Biol Trace Elem Res 2003; 94: 113-122.
15. Diez M, Cerdan FJ, Arroyo M, Balibrea JL,. Use of the copper/zinc ratio in the diagnosis of lung cancer. Cancer 1989; 63: 726-730.
16. Habib FK, Dembinski TC, Stitch SR,. The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clin Chim Acta 1980; 104: 329-335.
17. Maynard CJ, Cappai R, Volitakis I, Cherny RA, Masters CL, Li QX, Bush AI,. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: Implications for Alzheimer beta-amyloid pathology. J Inorg Biochem 2006; 100: 952-962.
18. Gupte A, Mumper RJ,. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009; 35: 32-46.
19. Tardito S, Bassanetti I, Bignardi C, Elviri L, Tegoni M, Mucchino C, Bussolati O, Franchi-Gazzola R, Marchio L,. Copper binding agents acting as copper ionophores lead to caspase inhibition and paraptotic cell death in human cancer cells. J Am Chem Soc 2011; 133: 6235-6242.
20. Holzer AK, Varki NM, Le QT, Gibson MA, Naredi P, Howell SB,. Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem 2006; 54: 1041-1049.
21. Toivanen R, Taylor RA, Pook DW, Ellem SJ, Risbridger GP,. Breaking through a roadblock in prostate cancer research: An update on human model systems. J Steroid Biochem Mol Biol. 2012; 131: 122-131.